PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis

BACKGROUND: The Food and Drug Administration has approved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia. However, evidence of the optimal PCSK9 agents targeting PCSK9 for secondary prevention in patients with high-risk of cardiovascular events is...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xing, Wen, Dingke, Chen, Yuqi, Ma, Lu, You, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202167/
https://www.ncbi.nlm.nih.gov/pubmed/35706032
http://dx.doi.org/10.1186/s12933-022-01542-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202167/
https://www.ncbi.nlm.nih.gov/pubmed/35706032
http://dx.doi.org/10.1186/s12933-022-01542-4

Ejemplares similares